THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced that the company has made the strategic decision to eliminate its commercial operations and ...

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027$10 million milestone payment triggered from licensing agreement ...

Lexicon (LXRX) Pharmaceuticals announced that the company has made the strategic decision to eliminate its commercial operations and rationalize resources across all functions in order to preserve ...

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and ...

THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development ...

THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a ...

Invus could invest up to $550 million, and Lexicon will provide $60 million to Symphony, created to develop Lexicon’s first three candidates. Lexicon Pharmaceuticals inked a $60-million deal with ...